Recent Research Analysts’ Ratings Updates for Evolent Health (EVH)

A number of firms have modified their ratings and price targets on shares of Evolent Health (NYSE: EVH) recently:

• 3/2/2026 – Evolent Health had its “buy” rating reaffirmed by TD Cowen.
• 3/2/2026 – Evolent Health had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $6.00. They now have an “outperform” rating on the stock.
• 2/28/2026 – Evolent Health was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/26/2026 – Evolent Health had its price target lowered by Citigroup Inc. from $6.00 to $4.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Evolent Health had its price target lowered by UBS Group AG from $10.00 to $5.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Evolent Health had its price target lowered by Truist Financial Corporation from $10.00 to $6.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Evolent Health had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $3.50 price target on the stock.
• 2/25/2026 – Evolent Health had its price target lowered by Needham & Company LLC from $15.00 to $4.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Evolent Health had its price target lowered by Royal Bank Of Canada from $5.00 to $3.00. They now have a “sector perform” rating on the stock.
• 2/25/2026 – Evolent Health had its price target lowered by BTIG Research from $10.00 to $8.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Evolent Health was downgraded by KeyCorp from “overweight” to “sector weight”.
• 2/2/2026 – Evolent Health had its price target lowered by BTIG Research from $16.00 to $10.00. They now have a “buy” rating on the stock.

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.